Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "DST"

109 News Found

Plant-based chemistry essential for home and personal care products:  Vishal Sharma, Executive Director & Chief Executive Officer (Chemicals), Godrej Industries
Opinion | July 17, 2025

Plant-based chemistry essential for home and personal care products: Vishal Sharma, Executive Director & Chief Executive Officer (Chemicals), Godrej Industries

Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products


Godavari Biorefineries' anti-cancer patent now validated in Spain and UK
Biotech | July 07, 2025

Godavari Biorefineries' anti-cancer patent now validated in Spain and UK

Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states


Borealis advancing sustainability medical devices with the Bornewables
Sustainability | May 13, 2025

Borealis advancing sustainability medical devices with the Bornewables

The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices


DHL Express and Sai Life Sciences sign GoGreen Plus partnership to make pharma deliveries more sustainable
Sustainability | April 24, 2025

DHL Express and Sai Life Sciences sign GoGreen Plus partnership to make pharma deliveries more sustainable

The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF


Innocan Pharma granted first patent in India for its Liposomal CBD Injection
News | February 20, 2025

Innocan Pharma granted first patent in India for its Liposomal CBD Injection

Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market


JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%
News | February 06, 2025

JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%

Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24


Wockhardt’s Zaynich achieves highest-ever efficacy meeting superiority in a global, pivotal, registration- enabling Phase III study
Clinical Trials | February 03, 2025

Wockhardt’s Zaynich achieves highest-ever efficacy meeting superiority in a global, pivotal, registration- enabling Phase III study

Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years


Piramal Pharma Q3 FY25 revenue up 13%
News | January 30, 2025

Piramal Pharma Q3 FY25 revenue up 13%

CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business